Nivalis Therapeutics, Inc. is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration. The Company's S-nitrosoglutathione reductase (GSNOR) inhibitors selectively target GSNOR. Depleted levels of S-nitrosoglutathione (GSNO) have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. The Company's lead product candidate, cavosonstat (N91115), is a small molecule inhibitor of GSNOR. cavosonstat is a pill that is in two Phase II clinical trials intended to address a defect in CF transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. Its preclinical studies have shown that cavosonstat is a selective and reversible inhibitor of GSNOR.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ALPN
- CUSIP: N/A
- Web: www.nivalis.com
- Market Cap: $31.7 million
- Outstanding Shares: 1,340,000
- 50 Day Moving Avg: $9.14
- 200 Day Moving Avg: $9.80
- 52 Week Range: $7.50 - $37.40
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.01
- P/E Growth: 0.00
- Annual Revenue: $2.95 million
- Price / Sales: 3.66
- Book Value: ($2.52) per share
- Price / Book: -3.20
- EBIDTA: ($3,170,000.00)
- Return on Equity: -53.23%
- Return on Assets: -48.85%
- Current Ratio: 13.90%
- Quick Ratio: 13.90%
- Average Volume: 19,384 shs.
- Beta: -0.02
- Short Ratio: 3.48
Frequently Asked Questions for Nivalis Therapeutics (NASDAQ:ALPN)
What is Nivalis Therapeutics' stock symbol?
Nivalis Therapeutics trades on the NASDAQ under the ticker symbol "ALPN."
How were Nivalis Therapeutics' earnings last quarter?
Nivalis Therapeutics, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Monday, February, 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.55) by $0.05. During the same period in the previous year, the firm earned ($0.42) EPS. View Nivalis Therapeutics' Earnings History.
Where is Nivalis Therapeutics' stock going? Where will Nivalis Therapeutics' stock price be in 2017?
7 brokerages have issued 12-month target prices for Nivalis Therapeutics' stock. Their forecasts range from $3.00 to $20.00. On average, they expect Nivalis Therapeutics' stock price to reach $10.88 in the next twelve months. View Analyst Ratings for Nivalis Therapeutics.
What are analysts saying about Nivalis Therapeutics stock?
Here are some recent quotes from research analysts about Nivalis Therapeutics stock:
- 1. According to Zacks Investment Research, "Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. " (8/10/2017)
- 2. Cowen and Company analysts commented, "This evening Nivalis and Alpine Immune Sciences announced an agreement to merge." (4/19/2017)
Who are some of Nivalis Therapeutics' key competitors?
Some companies that are related to Nivalis Therapeutics include Dipexium Pharmaceuticals (PLXP), Leap Therapeutics (LPTX), Endocyte (ECYT), Motif Bio PLC (MTFB), Rexahn Pharmaceuticals (RNN), Proteostasis Therapeutics (PTI), Avacta Group Plc (AVCT), OptiBiotix Health PLC (OPTI), Xenon Pharmaceuticals (XENE), Midatech Pharma PLC (MTPH), Aeglea BioTherapeutics (AGLE), Egalet Corporation (EGLT), Akari Therapeutics PLC (AKTX), Actinium Pharmaceuticals (ATNM), Imprimis Pharmaceuticals (IMMY), ContraVir Pharmaceuticals (CTRV), KemPharm (KMPH) and pSivida Corp. (PSDV).
Who are Nivalis Therapeutics' key executives?
Nivalis Therapeutics' management team includes the folowing people:
- Howard P. Furst M.D., Chairman of the Board
- R. Michael Carruthers, Interim President, Chief Financial Officer, Secretary
- Janice M. Troha, Chief Operating Officer
- Sherif Gabriel Ph.D., Vice President – Research and Discovery
- Steven Shoemaker M.D., Vice President – Clinical Research and Development, Medical Director
- Robert E. Conway, Independent Director
- Evan Loh M.D., Independent Director
- John R. Moore, Independent Director
- Paul Sekhri, Independent Director
How do I buy Nivalis Therapeutics stock?
Shares of Nivalis Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nivalis Therapeutics' stock price today?
MarketBeat Community Rating for Nivalis Therapeutics (NASDAQ ALPN)MarketBeat's community ratings are surveys of what our community members think about Nivalis Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Nivalis Therapeutics stock can currently be purchased for approximately $8.06.
Consensus Ratings for Nivalis Therapeutics (NASDAQ:ALPN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Hold Ratings, 3 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.43)|
|Consensus Price Target: ||$10.88 (34.93% upside)|
Analysts' Ratings History for Nivalis Therapeutics (NASDAQ:ALPN)
(Data available from 8/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|7/27/2017||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy -> Buy||$17.00||Low|
|4/19/2017||Cowen and Company||Reiterated Rating||Hold||Medium|
|11/29/2016||HC Wainwright||Reiterated Rating||Buy||$30.00 -> $6.00||N/A|
|11/29/2016||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform||N/A|
|11/29/2016||Robert W. Baird||Downgrade||Outperform -> Neutral||$29.00 -> $3.00||N/A|
|11/29/2016||Stifel Nicolaus||Downgrade||Buy -> Hold||$16.00 -> $3.25||N/A|
|8/30/2016||Piper Jaffray Companies||Reiterated Rating||Buy||$16.00||N/A|
Earnings History for Nivalis Therapeutics (NASDAQ:ALPN)Earnings History by Quarter for Nivalis Therapeutics (NASDAQ ALPN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Nivalis Therapeutics (NASDAQ:ALPN)
Current Year EPS Consensus Estimate: $-3.44 EPS
Next Year EPS Consensus Estimate: $-1.34 EPS
Dividend History for Nivalis Therapeutics (NASDAQ:ALPN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nivalis Therapeutics (NASDAQ:ALPN)
Insider Ownership Percentage: 3.00%Insider Trades by Quarter for Nivalis Therapeutics (NASDAQ:ALPN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/20/2017||Value Fund L P Biotechnology||Insider||Buy||17,806||$2.25||$40,063.50|| |
|6/7/2017||Bvf Partners L P/Il||Major Shareholder||Buy||36,900||$2.28||$84,132.00|| |
|6/7/2017||Value Fund L P Biotechnology||Insider||Buy||72,650||$2.29||$166,368.50|| |
|6/5/2017||Bvf Partners L P/Il||Major Shareholder||Buy||35,750||$2.29||$81,867.50|| |
|5/31/2017||Value Fund L P Biotechnology||Insider||Buy||47,000||$2.27||$106,690.00|| |
|5/19/2017||Value Fund L P Biotechnology||Insider||Buy||78,858||$2.30||$181,373.40|| |
|5/11/2017||Value Fund L P Biotechnology||Insider||Buy||109,034||$2.32||$252,958.88|| |
|5/9/2017||Robert E Conway||Director||Buy||5,000||$2.34||$11,700.00|| |
|5/8/2017||Robert E Conway||Director||Buy||15,000||$2.28||$34,200.00|| |
|5/5/2017||Janice Troha||EVP||Buy||10,000||$2.34||$23,400.00|| |
|5/5/2017||Robert E Conway||Director||Buy||20,000||$2.30||$46,000.00|| |
|5/4/2017||Robert E Conway||Director||Buy||10,000||$2.26||$22,600.00|| |
|1/4/2017||David Malcom Rodman||EVP||Sell||6,687||$2.27||$15,179.49|| |
|12/2/2016||R Michael Carruthers||EVP||Buy||24,000||$2.09||$50,160.00|| |
|10/4/2016||David Malcom Rodman||EVP||Sell||5,820||$7.96||$46,327.20|| |
|7/5/2016||David Malcom Rodman||CMO||Sell||5,950||$4.66||$27,727.00|| |
|6/16/2016||Jon Congleton||CEO||Buy||5,000||$3.87||$19,350.00|| |
|3/24/2016||Jon Congleton||CEO||Buy||5,000||$4.22||$21,100.00|| |
|3/22/2016||Jon Congleton||CEO||Buy||5,000||$4.38||$21,900.00|| |
|12/11/2015||Jon Congleton||CEO||Buy||5,000||$8.10||$40,500.00|| |
|12/9/2015||Robert E Conway||Director||Buy||10,000||$8.10||$81,000.00|| |
|6/23/2015||James E Flynn||Insider||Buy||250,000||$14.00||$3,500,000.00|| |
|6/22/2015||Bay Master Investors (C Hawkes||Major Shareholder||Buy||17,200||$14.69||$252,668.00|| |
|6/18/2015||Bay Master Investors (C Hawkes||Major Shareholder||Buy||20,400||$14.47||$295,188.00|| |
|6/17/2015||Global Healthcare Mas Jennison||Major Shareholder||Buy||26,149||$14.00||$366,086.00|| |
Headline Trends for Nivalis Therapeutics (NASDAQ:ALPN)
Latest Headlines for Nivalis Therapeutics (NASDAQ:ALPN)
Nivalis Therapeutics (ALPN) Chart for Saturday, August, 19, 2017